Dan Nicolae Tesloianu1, Corneliu Morosanu2, Ene-Cristian Roata2, Laurentiu Sorodoc3. 1. Department of Cardiology, "Sf. Spiridon" Emergency Clinical Hospital, Iasi, Romania. 2. Department of General Surgery, Regional Institute Of Oncology, Iasi, Romania. 3. Department of Internal Medicine, "Sf. Spiridon" Emergency Clinical Hospital, Iasi, Romania.
Abstract
INTRODUCTION: chronic peripheral arterial disease (PAD) seems to be a "rediscovered" pathology nowadays, brought into spotlight by its strong correlation with other signifi cant cardiovascular disorders. OBJECTIVES: to sustain a real benefi t from treatment with i.v. prostaglandins (PG) in PAD patients and to directly compare the currently used PG: alprostadil and iloprost. METHOD: open, non-randomized cohort study, with placebo group ("classical therapy") reviewing 615 PAD patients with therapeutic approach during 2003-2012 period, divided in 3 subgroups: "classical" therapy; "classical" therapy + iloprost; "classical" therapy + alprostadil; patients with Burger's disease were excluded; multiple factor analysis with statistical results inserted. RESULTS: clear domination of male gender patients, with older female gender patients (p.0.001); smoking like major risk factor in male and in all patients (p< 0.0001); 124 patients underwent angiography . CONCLUSION: a real improvement in the clinical status of patients receiving i.v. prostaglandin therapy with no diff erences between genders, diabetic and non-diabetic patients; alprostadil seems better than iloprost.
INTRODUCTION: chronic peripheral arterial disease (PAD) seems to be a "rediscovered" pathology nowadays, brought into spotlight by its strong correlation with other signifi cant cardiovascular disorders. OBJECTIVES: to sustain a real benefi t from treatment with i.v. prostaglandins (PG) in PAD patients and to directly compare the currently used PG: alprostadil and iloprost. METHOD: open, non-randomized cohort study, with placebo group ("classical therapy") reviewing 615 PAD patients with therapeutic approach during 2003-2012 period, divided in 3 subgroups: "classical" therapy; "classical" therapy + iloprost; "classical" therapy + alprostadil; patients with Burger's disease were excluded; multiple factor analysis with statistical results inserted. RESULTS: clear domination of male gender patients, with older female gender patients (p.0.001); smoking like major risk factor in male and in all patients (p< 0.0001); 124 patients underwent angiography . CONCLUSION: a real improvement in the clinical status of patients receiving i.v. prostaglandin therapy with no diff erences between genders, diabetic and non-diabeticpatients; alprostadil seems better than iloprost.
Authors: Michal Tendera; Victor Aboyans; Marie-Louise Bartelink; Iris Baumgartner; Denis Clément; Jean-Philippe Collet; Alberto Cremonesi; Marco De Carlo; Raimund Erbel; F Gerry R Fowkes; Magda Heras; Serge Kownator; Erich Minar; Jan Ostergren; Don Poldermans; Vincent Riambau; Marco Roffi; Joachim Röther; Horst Sievert; Marc van Sambeek; Thomas Zeller Journal: Eur Heart J Date: 2011-08-26 Impact factor: 29.983
Authors: S Occhionorelli; F Mascoli; G Vasquez; M Santini; G Navarra; P Carcoforo; I Donini Journal: Minerva Cardioangiol Date: 1995-06 Impact factor: 1.347